The current COVID-19 pandemic is affecting public health and economy worldwide. This pandemic has also affected the working and management strategies of clinical practices, healthcare centres, academics, and research centres. The academic and research institutions, students, and research scholars are diverging towards the online platform such as zoom and google meet for teaching, discussing, and sharing knowledge and ideas. Hospitals have also started following the concept of telemedicine for prescribing medicines to patients. In the current situation, on one side the research related to COVID-19 is conducted at an unprecedented rate whereas on the other side the research concerned with other fields including the CNS research is affected adversely. Initially, during the lockdown, the research activities were resumed, and even after the lockdown is withdrawn the situations are no longer better. It is very challenging to carry out the research activities at an adequate pace keeping in view the present pandemic situation.

Colorectal cancer (CRC) affects one in every 23 men and 25 women, making it the third most common cancer. CRC accounts for 8% of all cancer-related deaths, making it the second most common cause of death due to cancer. Standard and conventional CRC treatments include surgical expurgation for resectable CRC and radiotherapy, chemotherapy, immunotherapy, and their combinational regimen for non-resectable CRC. Despite these tactics, nearly half of patients develop incurable recurring CRC. These constraints necessitate the development of new target-specific therapeutic strategies such as targeted immune boosting therapies, non-coding RNAs based therapies, natural products, oncolytic viral therapies, have shown promising results in preclinical and clinical studies. We have tethered the entire evolutionary trends in the development of CRC treatments and have gone over the potential of new therapies and how they might be used in conjunction with conventional treatments, as well as their advantages and drawbacks as future medicines